The company will also highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies. The poster highlights the potential for ARV-393 ...

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, ...